HealthTree Logo
search more_vert
App Logo
close
person Sign In / Create Account
Clinical Trial: Using a Triple Combo (Elotuzumab, Lenalidomide and Dex) Before and After Transplant for Newly Diagnosed Myeloma
Posted: Apr 19, 2017
Clinical Trial: Using a Triple Combo (Elotuzumab, Lenalidomide and Dex) Before and After Transplant for Newly Diagnosed Myeloma image

Myeloma specialists are finding that the triple combinations are more effective than doublets in the treatment of multiple myeloma. Investigators want to know if using these triplets, especially those that include an immunotherapy like the monoclonal antibody elotuzumab (Empliciti) will improve outcomes for newly diagnosed patients who will receive a stem cell transplant.

In this Phase II study open at five centers, the triplet of elotuzumab, lenalidomide and dexamethasone will be used as induction therapy before transplant, and as consolidation therapy and maintenance after transplant for newly diagnosed myeloma patients.

To learn more, click the link below:

Elo/Len/Dex Myeloma Clinical Trial

Find all eligible clinical trials for your myeloma here.

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of HealthTree Foundation (formerly Myeloma Crowd). 

Get the latest thought leadership on Multiple Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Multiple Myeloma Newsletter" for Multiple Myeloma news, life with Multiple Myeloma stories, Multiple Myeloma clinical trials, Multiple Myeloma 101 articles and events with Multiple Myeloma experts.

Thanks to our HealthTree Community for Multiple Myeloma Sponsors:

Janssen Oncology
Adaptive Biotechnologies
Amgen Oncology
Abbvie
Genentech
GSK
Regeneron
Bristol Myers Squibb

Follow Us

facebook instagram twitter youtube